Axsome Therapeutics (AXSM) Misses Q4 EPS by 92c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($2.08), $0.92 worse than the analyst estimate of ($1.16). Revenue for the quarter came in at $71.53 million versus the consensus estimate of $68.83 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Casey's General Stores (CASY) Tops Q1 EPS by 69c
• JPMorgan Upgrades Lithium Americas Corp. (LAC) to Overweight